ImmuPharma Selects Thermo Fisher CDMO for Kapiglucagon
ImmuPharma has named Thermo Fisher Scientific’s Patheon as the drug product CDMO for Kapiglucagon, following the earlier selection of Bachem for API manufacturing, as it pushes the glucagon prodrug toward IND-enabling development for Type 1 diabetes and potential dual-hormone artificial pancreas applications. The company is pursuing a streamlined regulatory path, potentially a 505(b)(2) in the U.S., with plans to file an IND and begin first-in-human studies subject to regulatory confirmation.
Business · 5 sources · Jul 22, 2026Read itThe journal
Open the journal →The conversation starts in the journal — be the first to post.
About Bachem
Bachem Holding AG is a Swiss biotechnology company specializing in the development and manufacture of peptides and complex organic molecules for use as active pharmaceutical ingredients (APIs). The company focuses on peptide-based therapeutics, including large-scale commercial production and process development for pharmaceutical applications. It was founded in 1971 and is a subsidiary of Ingro Finanz AG.
Everything about Bachem →- Country
- Switzerland
- Headquarters
- Bubendorf
- Inception
- 1971
- Website
- http://www.bachem.com/